Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on World Healthcare Report.
Press releases published on August 28, 2025
Introducing ECP Engage: Marketing services tailored exclusively for optometry practices
GlobeNewswire
·
August 28, 2025
Toronto, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marketing plays a crucial role in growing an eye care practice and supporting patients. Today, digital-first PR firm Anamorphiq is launching a new service designed to help. ECP Engage is a suite of marketing …
LifeMD to Participate in Three Investor Conferences During September
GlobeNewswire
·
August 28, 2025
NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of September: Cantor …
Kestra Medical Technologies, Ltd. to Report First Quarter Fiscal 2026 Financial Results
GlobeNewswire
·
August 28, 2025
KIRKLAND, Wash., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced that it will report first quarter fiscal 2026 financial results on Thursday, …
Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences
GlobeNewswire
·
August 28, 2025
Osteoporosis Program: Phase 2 analysis exploring the dual actions of oral PTH(1-34) tablet treatment, EB613 on trabecular and cortical bone, and Next-Gen EB613 PK/PD data slated for oral and poster presentations at ASBMR Short Bowel Syndome and Rare GI …
Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
GlobeNewswire
·
August 28, 2025
NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced …
Stereotaxis Technology to be Featured at Heart Rhythm Society’s HRX 2025
GlobeNewswire
·
August 28, 2025
ST. LOUIS, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its technology will be featured during the upcoming HRX digital health …
Kura Oncology to Participate in Three Upcoming Investor Conferences
GlobeNewswire
·
August 28, 2025
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled …
Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences
GlobeNewswire
·
August 28, 2025
WAYNE, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic …
Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
August 28, 2025
MIAMI, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced management will …
EDAP Reports Strong Second Quarter 2025 HIFU Results
GlobeNewswire
·
August 28, 2025
+140% Focal One® Net Placement Growth Year over Year +76.8% HIFU Revenue Growth Year over Year 36 million Euro Credit Facility Letter of Intent Executed with European Investment Bank (EIB) to further accelerate HIFU Growth and Strategic Expansion Company …
Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
GlobeNewswire
·
August 28, 2025
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today …
AAVantgarde to Present Updated Clinical Data from LUCE-1 Study at EURetina 2025
GlobeNewswire
·
August 28, 2025
MILAN, Aug. 28, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced the presentation of updated LUCE-1 clinical data at the …
Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025
GlobeNewswire
·
August 28, 2025
CHATHAM, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced that …
SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel
GlobeNewswire
·
August 28, 2025
TEL AVIV, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, …
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
GlobeNewswire
·
August 28, 2025
FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLA Outlook Therapeutics plans to work with FDA to address the Agency’s issues Company to host a conference call and webcast today, August 28th at 8:30 AM ET ISELIN, N.J., Aug. 28, 2025 ( …
KFSHRC Advances Nursing Excellence Through Specialized Training
GlobeNewswire
·
August 28, 2025
RIYADH, Saudi Arabia, Aug. 28, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital …
ProNephro AKI™ (NGAL), til tidlig diagnosticering af akut nyreskade, er nu kommercielt tilgængelig på laboratorier i USA gennem BioPortos samarbejde med Roche Diagnostics.
GlobeNewswire
·
August 28, 2025
28. august 2025 Meddelelse ProNephro AKI™ (NGAL), til tidlig diagnosticering af akut nyreskade, er nu kommercielt tilgængelig på laboratorier i USA gennem BioPortos samarbejde med Roche Diagnostics. Samarbejdet med Roche Diagnostics markerer det første væ …
ProNephro AKI™ (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto’s collaboration with Roche Diagnostics.
GlobeNewswire
·
August 28, 2025
August 28, 2025 News Release ProNephro AKI™ (NGAL), early detection test for Acute Kidney Injury, now commercially available to US Labs through BioPorto’s collaboration with Roche Diagnostics. Collaboration with Roche Diagnostics is first major commercial …
TOLREMO therapeutics Receives Two FDA Fast Track Designations for TT125-802 in Pretreated, Advanced or Metastatic NSCLC With Either an EGFR or a KRAS-G12C Mutation
GlobeNewswire
·
August 28, 2025
TT125-802 is a small molecule CBP/p300 bromodomain inhibitor that shows clinical activity as single agent in solid tumors, including advanced EGFR-mutated and KRAS-G12C-mutated non-small cell lung cancer (NSCLC) 1 in 5 cancer-related deaths in the US are …
Oculis to Participate in Upcoming September Investor Conferences
GlobeNewswire
·
August 28, 2025
ZUG, Switzerland, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovative solutions for ophthalmic and neuro-ophthalmic diseases with significant unmet …